View Future GrowthOptiBiotix Health 과거 순이익 실적과거 기준 점검 0/6OptiBiotix Health 의 수입은 연평균 -64.2%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 5.5%의 비율로 증가해 왔습니다.핵심 정보-64.15%순이익 성장률-64.16%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률5.46%자기자본이익률-2.27%순이익률-16.59%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 29OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026. Location: the offices of marex, 155 bishopsgate, ec2m 3tq, london United Kingdom공시 • Feb 25OptiBiotix Health plc Announces Commencement of Clinical Study with Hull University Teaching Hospital Nhs TrustOptiBiotix Health plc announced the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes. This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotic like WellBiome in improving health outcomes and cost savings. WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: Nourishes beneficial bacteria throughout the entire gut to improve gut health; Contributes to improved bone health by aiding the absorption of essential minerals; Contributes to normal muscle function, including heart muscle; Supports normal brain health function and memory; Contributes to normal psychological function; Supports cardiovascular health; Contributes to a reduction of tiredness and fatigue.공시 • Nov 24OptiBiotix Health Plc Provides Update on its SweetBiotix Product Range for New and Existing InvestorsOptiBiotix Health plc provided an overview and update on its SweetBiotix product range for new and existing investors. SweetBiotix®? are a portfolio of natural, sweet, high fibre, low-calorie products developed to replace sugar and sugar substitutes. They are produced using a patented technology developed by OptiBiotix which enzymatically modifies existing natural sweeteners like steviol glycosides and mogrosides and converts them into dietary fibres, providing sweetness with added nutritional and health benefits. SweetBiotix are trademarked and patented products protected by a significant intellectual property portfolio comprising over 25 patents with a number of recent additional filings. Patients must demonstrate novelty/uniqueness, inventiveness (i.e. no one else has invented it), and industry applicability confirming the uniqueness of SweetBiotix. SweetBiotix are unique as a sugar substitute as they have been developed to overcome health concerns, are high in fibre, and have prebiotic functionality providing nutritional and health benefits not present in existing products. This a market estimated to be worth $29.9 billion by 2029 (Markets and Markets: Oct 2024). What is the evidence that SweetBiotix are sweet and have health benefits SweetBiotix products have been tested by academic groups who have published five papers in peer reviewed journals providing an independent assessment of SweetBiotix's taste and health benefits. One publication on an early SweetBiotix product concluded ' This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fiber functionality'. The Company has provided SweetBiotix samples under Material Transfer Agreements (MTA) to a number of partners, many of whom have specialist expertise in taste testing and sugar substitutes. This has led to a formal agreement with a USA partner and DSM Firmenich, a $12 billion ingredients supplier, and several food and beverage companies supporting SweetBiotix development with a view to the use of SweetBiotix in their products. This changes the positioning with sugar producers who have previously seen SweetBiotix as a competitor, to a potential partner, by offering a unique, patented process which can utilise and modify commoditised sucrose into higher valued SweetBiotix products. Importantly, whilst there is a material change in the enzymatic process there is no change to the resulting SweetBiotix product other than higher yields which significantly increases the purity (90%) of the final product. The Company believes that most of the process changes are covered within its existing patent portfolio but has extended its filings on the enzyme use and composition given the uniqueness and commercial potential of their properties. Next steps The Company is producing quantities of SweetBiotix for its development, manufacturing, and application partners and sharing the new enzymatic process with DSM Firmenich, US partner, and major sugar producers given its potential to valorise sugar. The Company continues to receive an annual milestone of PS100k from its US partner related to work on Mogrosides with total received to end of 2024 of PS550k. Milestone payments are rarely seen in the food, beverage and supplement industry, even less so prior to commercial launch and should give investors' confidence in the value attributed to this technology by industry. Subject to any partner constraints, the Company hopes to be in a position to demonstrate a range of SweetBiotix products to investors in first first half of 2026. Subject to any partner restrictions, the Company hopes to be In addition to any partner constraints, the company hopes to be in a positions to demonstrate a range of Sweet Biotix products to investors in H1 2026. The Company has made a breakthrough in improving the manufacturing process of its SweetBiotix products. By using a new enzyme, rather than an enzyme extract, the Company is able to achieve substantially higher yields of a purer, more concentrated, better tasting product with lower ingredient and production costs. These are significant benefits when producing at large scale. This new enzyme works on both mogrosides and stevia glycosides allowing the generation of multiple SweetBiotix products to multiple SweetBiotix products.공시 • Jun 29OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024. Location: the offices of peterhouse capital limited, 3rd floor, 80 cheapside, ec2v 6ee, london United Kingdom공시 • Jun 21OptiBiotix Health Plc Announces Slimbiome Study ResultsOptiBiotix Health plc notes the latest results from the human studies carried out at Roehampton University, London on OptiBiotix's SlimBiome. Study outcomes, awaiting publication, suggested SlimBiome® intake had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption. This is one of four studies which have consistently shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and changing the type of food they eat, to less calorie intense food leading to sustainable weight management. This suggests that SlimBiome® can be used as a natural alternative to the current anti-obesity drugs on the market. These findings on the acute impact of one dose of SlimBiome® are consistent with those of a previous first study, also carried out by Professor Adele Costabile, published in the Journal of Functional Foods (November 2020) which showed that volunteers taking SlimBiome® for four weeks experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. SlimBiome® is availableherein sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars, gummies, and soups/porridges and is increasingly being used by major sports nutrition brands to support lean body development. The latest results from human studies reinforce findings that a mineral enriched prebiotic fibre complex can help reduce hunger by 27% and support the feeling of fullness by 35% offering a rapid and natural solution for those seeking support in weight management. The latest results from a study conducted by Professor Adele Costabile at the University of Roehampton using Optibitix's SlimBiome® saw 20 volunteers given 50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes, awaiting publication, suggested SlimBiome® intake had a significant impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness for over two hours after consumption. These findings on the acute impact of one dose of SlimBiome are consistent with those of a previous first study, also carried out by Professor Adele and her team, published in the Journal of Functional Foods (November 2020) which showed that taking SlimBiome® for four weeks volunteers experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. Overall, 90% of volunteers lost weight and all volunteers reported a reduction in waist and hip circumference and lost body fat. In addition, volunteers improved their mood by 26%, suggesting they were losing weight without feeling hungry or craving for food making it more sustainable. The results also showed a significant change in volunteers gut microbiome with a statistically significant increase in microbes associated with a lean body. These studies suggest that a natural ingredient like SlimBiome®, which was tolerated well in all studies, may offer a natural approach to managing hunger and food cravings to support weight management. Whilst using different mechanisms of action, SlimBiome® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying.공시 • Jan 15OptiBiotix Health PlcAnnounces Launch of LeanBiome in MuscletechOptiBiotix Health plc announced the forthcoming launch of LeanBiome in Muscletech,one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company. The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK. Muscletech®is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world.LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and willbe launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels. LeanBiome®is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome®contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes.공시 • Dec 04Optibiotix Health plc Appoints Graham Myers as Finance DirectorOptiBiotix Health Plc announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023. Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme. Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support thefocus on driving each business unit and the Group to profitability.공시 • Jul 27OptiBiotix Health plc Announces Cessation of DirectorsFurther to the announcement of 28 June 2023, OptiBiotix Health Plc confirms that Non-executive Directors Stephen Hammond and Chris Brinsmead have not put themselves for re-election as Directors and have therefore, with immediate effect, ceased to be Directors of the Company.공시 • Jul 21OptiBiotix Health plc Provides an Overview of its SweetBiotix Product RangeOptiBiotix Health plc provided an overview of its SweetBiotix product range in the light of recent news interest in sweeteners. Meeting the market need: OptiBiotix has developed a portfolio of novel, patented, zero or low calorie sweet dietary fibres, called SweetBiotix. They are unique in that they do not have the health concerns associated with sugar, corn syrup, or sweeteners and importantly, from a health and nutritional labelling perspective, are classified as dietary fibres. In addition to the benefits of increasing fibre intake, SweetBiotix fibres have been shown to have a prebiotic effect by increasing the production of short chain fatty acids. SCFAs are widely known for their importance in gut health, immunity and how energy is metabolised in the body and are one of the main ways in which the gut microbiome contributes to better health. This creates a clear differentiator to other products on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right. The SweetBiotix portfolio contains a range of products which human studies have shown have high (240X the sweetness of sugar) to moderate levels of sweetness (3X) to meet the needs of a wide range of application including fizzy drinks, snacks, bakery products, dairy products and cereals. As a general guide, the high-level sweet products could be considered a replacement for existing sweeteners whilst the moderate level sweetness products as bulk sugar replacement products. The strategy is designed to create multiple opportunities which offer added value and use for a wide range of product applications. Whist taking longer, this reduces the commercial risk which would exist with a single product approach whilst increasing the scale of the opportunity. Product developments OptiBiotix'sproducts are differentiated from other natural sweeteners and sugar substitutes on the market in that they have been developed: To be classified on packaging as dietary fibres providing no contribution to sugar intake and enhancing product nutritional labels. Have a low glycemic index (reducing the risk of developing diabetes). Enhance the gut microbiome providing additional potential health benefits. Have intense sweetness (High Intensity Sweeteners) or sweetness similar to sugar (depending on product). Current position: Both product types are at the end stage of manufacturing scale up with ongoing testing of samples with both partners. This is a complex and rigorous process. Typically, global partners with established brands require confirmation of a robust supply chain for all ingredients (ethically and responsibly sourced) from two different suppliers, low waste streams, humans studies/taste tests and structural and functional analysis on liquid and freeze-dried products from three different production runs to show there is no batch to batch variability. In addition, most require two year shelf life of SweetBiotix as an ingredient and in their final products with no observable effect on appearance, taste, or texture or functionality.공시 • Jun 28OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023, at 10:00 Coordinated Universal Time. Location: Walbrook PR Ltd, 75 King William Street London, United Kingdom Agenda: To consider re-election as directors of the Company and will therefore cease to be directors following the conclusion of the AGM.공시 • Dec 06OptiBiotix Health Plc announced that it has received £0.5 million in fundingOptiBiotix Health Plc announced a private placement to issued 3,125,000 new ordinary shares of par value £0.02 per share, at an issue price of £0.16 per new ordinary share for gross proceeds of £500,000 on December 5, 2022.매출 및 비용 세부 내역OptiBiotix Health가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:OPTB.F 매출, 비용 및 순이익 (GBP Millions)날짜매출순이익일반관리비연구개발비30 Jun 25103031 Mar 251-13031 Dec 241-22030 Sep 241-22030 Jun 241-32031 Mar 241-32031 Dec 231-22030 Sep 231-82030 Jun 231-132031 Mar 231-52031 Dec 22033030 Sep 22142030 Jun 22162031 Mar 22262031 Dec 21262030 Sep 212132030 Jun 212212031 Mar 212132031 Dec 20262031 Dec 191-22031 May 191-22028 Feb 191-22030 Nov 181-22031 Aug 180-22031 May 180-22028 Feb 18002030 Nov 17022031 Aug 17022031 May 17021028 Feb 17011030 Nov 160-11031 Aug 160-11031 May 160-11029 Feb 160-11030 Nov 150-11031 Aug 150-11031 May 150-110양질의 수익: OPTB.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: OPTB.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: OPTB.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 64.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 OPTB.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: OPTB.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: OPTB.F는 현재 수익성이 없으므로 자본 수익률이 음수(-2.27%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/01/27 10:14종가2025/10/30 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스OptiBiotix Health Plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 29OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026. Location: the offices of marex, 155 bishopsgate, ec2m 3tq, london United Kingdom
공시 • Feb 25OptiBiotix Health plc Announces Commencement of Clinical Study with Hull University Teaching Hospital Nhs TrustOptiBiotix Health plc announced the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes. This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotic like WellBiome in improving health outcomes and cost savings. WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: Nourishes beneficial bacteria throughout the entire gut to improve gut health; Contributes to improved bone health by aiding the absorption of essential minerals; Contributes to normal muscle function, including heart muscle; Supports normal brain health function and memory; Contributes to normal psychological function; Supports cardiovascular health; Contributes to a reduction of tiredness and fatigue.
공시 • Nov 24OptiBiotix Health Plc Provides Update on its SweetBiotix Product Range for New and Existing InvestorsOptiBiotix Health plc provided an overview and update on its SweetBiotix product range for new and existing investors. SweetBiotix®? are a portfolio of natural, sweet, high fibre, low-calorie products developed to replace sugar and sugar substitutes. They are produced using a patented technology developed by OptiBiotix which enzymatically modifies existing natural sweeteners like steviol glycosides and mogrosides and converts them into dietary fibres, providing sweetness with added nutritional and health benefits. SweetBiotix are trademarked and patented products protected by a significant intellectual property portfolio comprising over 25 patents with a number of recent additional filings. Patients must demonstrate novelty/uniqueness, inventiveness (i.e. no one else has invented it), and industry applicability confirming the uniqueness of SweetBiotix. SweetBiotix are unique as a sugar substitute as they have been developed to overcome health concerns, are high in fibre, and have prebiotic functionality providing nutritional and health benefits not present in existing products. This a market estimated to be worth $29.9 billion by 2029 (Markets and Markets: Oct 2024). What is the evidence that SweetBiotix are sweet and have health benefits SweetBiotix products have been tested by academic groups who have published five papers in peer reviewed journals providing an independent assessment of SweetBiotix's taste and health benefits. One publication on an early SweetBiotix product concluded ' This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fiber functionality'. The Company has provided SweetBiotix samples under Material Transfer Agreements (MTA) to a number of partners, many of whom have specialist expertise in taste testing and sugar substitutes. This has led to a formal agreement with a USA partner and DSM Firmenich, a $12 billion ingredients supplier, and several food and beverage companies supporting SweetBiotix development with a view to the use of SweetBiotix in their products. This changes the positioning with sugar producers who have previously seen SweetBiotix as a competitor, to a potential partner, by offering a unique, patented process which can utilise and modify commoditised sucrose into higher valued SweetBiotix products. Importantly, whilst there is a material change in the enzymatic process there is no change to the resulting SweetBiotix product other than higher yields which significantly increases the purity (90%) of the final product. The Company believes that most of the process changes are covered within its existing patent portfolio but has extended its filings on the enzyme use and composition given the uniqueness and commercial potential of their properties. Next steps The Company is producing quantities of SweetBiotix for its development, manufacturing, and application partners and sharing the new enzymatic process with DSM Firmenich, US partner, and major sugar producers given its potential to valorise sugar. The Company continues to receive an annual milestone of PS100k from its US partner related to work on Mogrosides with total received to end of 2024 of PS550k. Milestone payments are rarely seen in the food, beverage and supplement industry, even less so prior to commercial launch and should give investors' confidence in the value attributed to this technology by industry. Subject to any partner constraints, the Company hopes to be in a position to demonstrate a range of SweetBiotix products to investors in first first half of 2026. Subject to any partner restrictions, the Company hopes to be In addition to any partner constraints, the company hopes to be in a positions to demonstrate a range of Sweet Biotix products to investors in H1 2026. The Company has made a breakthrough in improving the manufacturing process of its SweetBiotix products. By using a new enzyme, rather than an enzyme extract, the Company is able to achieve substantially higher yields of a purer, more concentrated, better tasting product with lower ingredient and production costs. These are significant benefits when producing at large scale. This new enzyme works on both mogrosides and stevia glycosides allowing the generation of multiple SweetBiotix products to multiple SweetBiotix products.
공시 • Jun 29OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024. Location: the offices of peterhouse capital limited, 3rd floor, 80 cheapside, ec2v 6ee, london United Kingdom
공시 • Jun 21OptiBiotix Health Plc Announces Slimbiome Study ResultsOptiBiotix Health plc notes the latest results from the human studies carried out at Roehampton University, London on OptiBiotix's SlimBiome. Study outcomes, awaiting publication, suggested SlimBiome® intake had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption. This is one of four studies which have consistently shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and changing the type of food they eat, to less calorie intense food leading to sustainable weight management. This suggests that SlimBiome® can be used as a natural alternative to the current anti-obesity drugs on the market. These findings on the acute impact of one dose of SlimBiome® are consistent with those of a previous first study, also carried out by Professor Adele Costabile, published in the Journal of Functional Foods (November 2020) which showed that volunteers taking SlimBiome® for four weeks experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. SlimBiome® is availableherein sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars, gummies, and soups/porridges and is increasingly being used by major sports nutrition brands to support lean body development. The latest results from human studies reinforce findings that a mineral enriched prebiotic fibre complex can help reduce hunger by 27% and support the feeling of fullness by 35% offering a rapid and natural solution for those seeking support in weight management. The latest results from a study conducted by Professor Adele Costabile at the University of Roehampton using Optibitix's SlimBiome® saw 20 volunteers given 50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes, awaiting publication, suggested SlimBiome® intake had a significant impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness for over two hours after consumption. These findings on the acute impact of one dose of SlimBiome are consistent with those of a previous first study, also carried out by Professor Adele and her team, published in the Journal of Functional Foods (November 2020) which showed that taking SlimBiome® for four weeks volunteers experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. Overall, 90% of volunteers lost weight and all volunteers reported a reduction in waist and hip circumference and lost body fat. In addition, volunteers improved their mood by 26%, suggesting they were losing weight without feeling hungry or craving for food making it more sustainable. The results also showed a significant change in volunteers gut microbiome with a statistically significant increase in microbes associated with a lean body. These studies suggest that a natural ingredient like SlimBiome®, which was tolerated well in all studies, may offer a natural approach to managing hunger and food cravings to support weight management. Whilst using different mechanisms of action, SlimBiome® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying.
공시 • Jan 15OptiBiotix Health PlcAnnounces Launch of LeanBiome in MuscletechOptiBiotix Health plc announced the forthcoming launch of LeanBiome in Muscletech,one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company. The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK. Muscletech®is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world.LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and willbe launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels. LeanBiome®is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome®contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes.
공시 • Dec 04Optibiotix Health plc Appoints Graham Myers as Finance DirectorOptiBiotix Health Plc announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023. Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme. Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support thefocus on driving each business unit and the Group to profitability.
공시 • Jul 27OptiBiotix Health plc Announces Cessation of DirectorsFurther to the announcement of 28 June 2023, OptiBiotix Health Plc confirms that Non-executive Directors Stephen Hammond and Chris Brinsmead have not put themselves for re-election as Directors and have therefore, with immediate effect, ceased to be Directors of the Company.
공시 • Jul 21OptiBiotix Health plc Provides an Overview of its SweetBiotix Product RangeOptiBiotix Health plc provided an overview of its SweetBiotix product range in the light of recent news interest in sweeteners. Meeting the market need: OptiBiotix has developed a portfolio of novel, patented, zero or low calorie sweet dietary fibres, called SweetBiotix. They are unique in that they do not have the health concerns associated with sugar, corn syrup, or sweeteners and importantly, from a health and nutritional labelling perspective, are classified as dietary fibres. In addition to the benefits of increasing fibre intake, SweetBiotix fibres have been shown to have a prebiotic effect by increasing the production of short chain fatty acids. SCFAs are widely known for their importance in gut health, immunity and how energy is metabolised in the body and are one of the main ways in which the gut microbiome contributes to better health. This creates a clear differentiator to other products on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right. The SweetBiotix portfolio contains a range of products which human studies have shown have high (240X the sweetness of sugar) to moderate levels of sweetness (3X) to meet the needs of a wide range of application including fizzy drinks, snacks, bakery products, dairy products and cereals. As a general guide, the high-level sweet products could be considered a replacement for existing sweeteners whilst the moderate level sweetness products as bulk sugar replacement products. The strategy is designed to create multiple opportunities which offer added value and use for a wide range of product applications. Whist taking longer, this reduces the commercial risk which would exist with a single product approach whilst increasing the scale of the opportunity. Product developments OptiBiotix'sproducts are differentiated from other natural sweeteners and sugar substitutes on the market in that they have been developed: To be classified on packaging as dietary fibres providing no contribution to sugar intake and enhancing product nutritional labels. Have a low glycemic index (reducing the risk of developing diabetes). Enhance the gut microbiome providing additional potential health benefits. Have intense sweetness (High Intensity Sweeteners) or sweetness similar to sugar (depending on product). Current position: Both product types are at the end stage of manufacturing scale up with ongoing testing of samples with both partners. This is a complex and rigorous process. Typically, global partners with established brands require confirmation of a robust supply chain for all ingredients (ethically and responsibly sourced) from two different suppliers, low waste streams, humans studies/taste tests and structural and functional analysis on liquid and freeze-dried products from three different production runs to show there is no batch to batch variability. In addition, most require two year shelf life of SweetBiotix as an ingredient and in their final products with no observable effect on appearance, taste, or texture or functionality.
공시 • Jun 28OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023, at 10:00 Coordinated Universal Time. Location: Walbrook PR Ltd, 75 King William Street London, United Kingdom Agenda: To consider re-election as directors of the Company and will therefore cease to be directors following the conclusion of the AGM.
공시 • Dec 06OptiBiotix Health Plc announced that it has received £0.5 million in fundingOptiBiotix Health Plc announced a private placement to issued 3,125,000 new ordinary shares of par value £0.02 per share, at an issue price of £0.16 per new ordinary share for gross proceeds of £500,000 on December 5, 2022.